DEERFIELD MANAGEMENT COMPANY, L.P.
CIK 1009258 · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$434.20M
Companies
40
Total Filings
76
Lifetime Open-Market Net
$556.91M
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AFIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestOfficerDirector10% owner* stale (no filing in 3 yrs)
Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Reported Address
345 PARK AVENUE SOUTH, 12TH FLOORNEW YORK, NY 10010
Phone
(212) 551-1600
State of Incorporation
DE
Formerly Known As
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2018–2025)
DEERFIELD MANAGEMENT CO (2013–2017)
DEERFIELD MANAGEMENT CO /NY (1999–2013)
DEERFIELD MANAGEMENT/NY (1996–1996)
Related Filers
James E Flynn — 442 joint filings, latest 2026-07-17
Deerfield Mgmt L.P. — 379 joint filings, latest 2026-07-17
Deerfield Special Situations Fund, L.P. — 276 joint filings, latest 2021-07-13
DEERFIELD PARTNERS, L.P. — 197 joint filings, latest 2026-07-17
Deerfield Special Situations Fund International LTD — 142 joint filings, latest 2013-07-18
Deerfield Mgmt III, L.P. — 81 joint filings, latest 2026-06-11
Deerfield Private Design Fund III, L.P. — 81 joint filings, latest 2026-06-11
DEERFIELD INTERNATIONAL LTD — 63 joint filings, latest 2011-06-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Nuvalent, Inc. (NUVL) Delisted | Director | 0 | $123.96 | $0 | $0 | 6 | 2026-07-17 |
| PBLS | 10%+ Owner | 533,220 | $26.37 | $14.06M | $0 | 1 | 2026-06-11 |
| LRMR | Director | — | $2.33 | — | $0 | 7 | 2026-05-20 |
| BiomX Inc. (PHGE) Delisted | Director | 65,634 | $1.85 | $121.4K | $0 | 2 | 2025-04-18 |
| SPRY | 10%+ Owner | 5,257,329 | $3.83 | $20.16M | -$60.86M | 1 | 2024-11-13 |
| BiomX Inc. (PHGE.U) Delisted | Director | 3,055,049 | $0.90 | $2.75M | $0 | 2 | 2024-07-15 |
| Acutus Medical, Inc. (AFIB) Delisted | Director | 1,026,243 | $0.09 | $92.4K | $252.00M | 4 | 2023-06-20 |
| CareMax, Inc. (CMAXW) Delisted | Director | — | $0.01 | — | $0 | 2 | 2023-06-12 |
| Oncology Institute, Inc. (TOI) Delisted | 10%+ Owner | 1,605,477 | $5.13 | $8.24M | $0 | 1 | 2021-11-16 |
| Oncology Institute, Inc. (DFPHU) Delisted | Director | 2,500,000 | $10.26 | $25.65M | $0 | 1 | 2020-03-17 |
| BDTX | 10%+ Owner | 778,790 | $1.73 | $1.34M | $30.40M | 1 | 2020-02-03 |
| MIRM | 10%+ Owner | 1,558,456 | $84.01 | $130.93M | $39.84M | 1 | 2019-07-24 |
| ACRS | 10%+ Owner | 1,072,775 | $3.69 | $3.96M | -$38.4K | 2 | 2019-06-26 |
| FIXX | Director | 64,352 | $7.24 | $465.9K | $96.00M | 2 | 2019-04-15 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | 10%+ Owner | 2,675,638 | $15.25 | $40.80M | $0 | 1 | 2018-07-23 |
| PRTO | Director | — | $27.11 | — | $0 | 1 | 2018-06-12 |
| KNSA | 10%+ Owner | 843,352 | $86.99 | $73.36M | $79.98M | 1 | 2018-05-31 |
| AdaptHealth Corp. (VTL) Delisted | Director | 62,500 | — | — | $0 | 1 | 2018-04-04 |
| CAS MEDICAL SYSTEMS INC (CASM) Delisted | 10%+ Owner | 2,947,554 | — | — | -$3.72M | 1 | 2017-01-26 |
| Invuity, Inc. (IVTY) Delisted | 10%+ Owner | 1,807,239 | — | — | -$4.60M | 1 | 2016-12-14 |
| VNDA | 10%+ Owner | 2,660,207 | $4.00 | $10.63M | $42.54M | 4 | 2016-09-19 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Director | — | — | — | $0 | 1 | 2016-09-14 |
| AXGN | 10%+ Owner | 3,102,136 | $38.08 | $118.13M | -$10.29M | 2 | 2016-07-18 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 62,857 | $0.00 | $25 | $30.00M | 1 | 2016-07-06 |
| XENOPORT INC (XNPT) Delisted | 10%+ Owner | 6,667,391 | — | — | $418.2K | 1 | 2016-02-23 |
| AveXis, Inc. (AVXS) Delisted | 10%+ Owner | 249,909 | — | — | $116.84M | 1 | 2016-02-19 |
| ANTARES PHARMA, INC. (ATRS) Delisted | 10%+ Owner | 7,818,639 | $5.59 | $43.71M | -$7.29M | 2 | 2015-07-21 |
| LIFE | 10%+ Owner | 18,269 | $42.51 | $776.6K | $4.20M | 1 | 2015-05-13 |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | 48,388 | $0.09 | $4.3K | $11.20M | 1 | 2015-02-19 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2014-09-25 |
| MEDICINES CO /DE (MDCO) Delisted | 10%+ Owner | 2,454,261 | — | — | -$34.90M | 1 | 2011-04-06 |
| NxStage Medical, Inc. (NXTM) Delisted | 10%+ Owner | 875,072 | — | — | -$14.65M | 2 | 2009-10-13 |
| SALIX PHARMACEUTICALS LTD (SLXP) Delisted | 10%+ Owner | 2,186,025 | — | — | $2.26M | 3 | 2009-07-29 |
| DUSA | 10%+ Owner | 1,064,317 | $56.73 | $60.38M | $1.90M | 1 | 2009-06-26 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | 10%+ Owner | 1,357,068 | — | — | -$7.25M | 1 | 2008-12-01 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | 10%+ Owner | 493,713 | — | — | -$7.02M | 1 | 2008-10-21 |
| NITROMED INC (NTMD) Delisted | 10%+ Owner | 3,406,117 | — | — | $1.38M | 3 | 2008-07-15 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | 10%+ Owner | 186,174 | $99.99 | $18.62M | -$1.31M | 1 | 2007-10-23 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 1,296,399 | — | — | -$127.5K | 1 | 2007-10-19 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | — | $15.50 | — | $0 | 1 | 2007-07-23 |
Recent Filings · Page 7 of 8
76 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-10-13 | NxStage Medical, Inc. (NXTM) Delisted | Sell (S) | −104,418 | -$703.6K | EDGAR |
| 2009-09-16 | NxStage Medical, Inc. (NXTM) Delisted | Sell (S) | −2,039,742 | -$13.95M | EDGAR |
| 2009-07-29 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Sell (S) | −507,720 | -$6.69M | EDGAR |
| 2009-07-10 | — | Sell (S) | −118,470 | -$701.8K | |
| 2009-06-26 | DUSA | Buy (P) | +2,115,000 | $1.90M | EDGAR |
| 2009-06-25 | — | Sell (S) | −416,635 | -$2.60M | |
| 2009-01-02 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Buy (P) | +345,250 | $3.01M | EDGAR |
| 2008-12-24 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Buy (P) | +704,530 | $5.95M | EDGAR |
| 2008-12-01 | PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | Sell (S) | −694,000 | -$7.25M | EDGAR |
| 2008-10-21 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Sell (S) | −3,220,000 | -$7.02M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.